Would you use lapatinib to prevent recurrence of brain mets in a patient with recurrent brain-only mets from HER2+ breast cancer now rendered NED after radiation?  

Options for treating a patient like this are quite numerous and could include lapatinib among other possibilities. Lapatinib, especially when combined with capecitabine, showed good response rates in the CNS. Lapatinib has better CNS penetration than other anti-HER2 agents. However, it is important ...